{
  "source": "PA-Notification-Vitrakvi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1271-7\nProgram Prior Authorization/Notification\nMedication Vitrakvi® (larotrectinib)\nP&T Approval Date 1/2019, 1/2020, 1/2021, 1/2022, 1/2023, 1/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nVitrakvi® (larotrectinib) is a kinase inhibitor indicated for the treatment of adult and pediatric\npatients with solid tumors that:\n• have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired\nresistance mutation,\n• are metastatic or where surgical resection is likely to result in severe morbidity, and\n• have no satisfactory alternative treatments or that have progressed following treatment.\nThis indication is approved under accelerated approval based on overall response rate and\nduration of response. Continued approval for this indication may be contingent upon verification\nand description of clinical benefit in confirmatory trials.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Vitrakvi will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Solid Tumors\n1. Initial Authorization\na. Vitrakvi will be approved based on all of the following criteria:\n(1) Presence of a solid tumor\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Disease is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion\n(e.g. ETV6-NTRK3, TPM3-NTRK1, LMNA-NTRK1, etc.)\n-AND-\n(3) Disease is without a known acqu",
    "althcare Services, Inc.\n1\n(2) Disease is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion\n(e.g. ETV6-NTRK3, TPM3-NTRK1, LMNA-NTRK1, etc.)\n-AND-\n(3) Disease is without a known acquired resistance mutation (e.g., TRKA G595R,\nG623R, G696A, F617L.).\n-AND-\n(4) Disease is one of the following:\n(a) Metastatic\n(b) Unresectable\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Vitrakvi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Vitrakvi therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of\nEvidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Vitrakvi [package insert]. Bayer HealthCare Pharmaceuticals Inc.: Whippany, NJ; November\n2023.\n© 2025 UnitedHealthcare Services, Inc.\n2\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed November\n27, 2024.\nProgram Prior Authorization/Notification - Vitrakvi® (larotrectinib)\nChange Control\n1/2019 New program.\n1/2020 Annual review. Added general NCCN recommendations for use criteria.\nUpdated references.\n1/2021 Annual review. Removed listed",
    "ation - Vitrakvi® (larotrectinib)\nChange Control\n1/2019 New program.\n1/2020 Annual review. Added general NCCN recommendations for use criteria.\nUpdated references.\n1/2021 Annual review. Removed listed solid tumor examples since list was not all\ninclusive. No change to coverage criteria. Updated references.\n1/2022 Annual review with no change to clinical criteria. Updated resistant\nmutation examples to reflect package insert. Updated references.\n1/2023 Annual review. Removed criteria requiring previous treatment progression\nor no alternative therapy based on first line recommendations per NCCN\nfor certain cancers. Added state mandate footnote. Updated reference.\n1/2024 Annual review with no changes to clinical criteria. Updated references.\n1/2025 Annual review with no changes to clinical criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}